UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063696
Receipt number R000072870
Scientific Title Prospective Real-world Observational Study of Diagnostic Processes and Management of Nontuberculous Mycobacterial Pulmonary Disease in Japan (Pro-NTM-PD)
Date of disclosure of the study information 2026/11/20
Last modified on 2026/11/18 16:31:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective Real-world Observational Study of Diagnostic Processes and Management of Nontuberculous Mycobacterial Pulmonary Disease in Japan (Pro-NTM-PD)

Acronym

Study of Real-World Clinical Practice for Nontuberculous Mycobacterial Pulmonary Disease

Scientific Title

Prospective Real-world Observational Study of Diagnostic Processes and Management of Nontuberculous Mycobacterial Pulmonary Disease in Japan (Pro-NTM-PD)

Scientific Title:Acronym

Study of Real-World Clinical Practice for Nontuberculous Mycobacterial Pulmonary Disease

Region

Japan


Condition

Condition

Nontuberculous Mycobacterial Pulmonary Disease

Classification by specialty

Pneumology Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To prospectively describe the diagnostic and clinical management processes of patients with NTM-PD in Japan, from symptom onset or detection of abnormal imaging findings through medical consultations, diagnostic testing, diagnosis, referral to institutions specializing in NTM-PD care, and treatment decisions. The study also aims to describe clinical practices at referring institutions, the timing and reasons for referral, treatment and clinical outcomes at specialized institutions, and the distribution of mycobacterial species and antimicrobial susceptibility patterns.

Basic objectives2

Others

Basic objectives -Others

Investigation of diagnostic, referral, and treatment processes and exploration of associated factors

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Time (in days) from the first visit to the referring healthcare institution to the first visit to an institution specializing in NTM-PD care.

Key secondary outcomes

Reasons for referral to institutions specializing in NTM-PD care; diagnostic tests and clinical practices at referring healthcare institutions; treatment status at participating institutions; distribution of mycobacterial species and antimicrobial susceptibility patterns; treatment regimens, clinical course, and reasons for changes in treatment; and clinical outcomes, including sputum culture conversion, recurrence, and survival.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients with confirmed NTM-PD newly referred to a participating institution specializing in NTM-PD care, or patients newly diagnosed with NTM-PD at a participating institution according to the diagnostic or provisional diagnostic criteria of the Japanese Society for Tuberculosis and Nontuberculous Mycobacteriosis, between the date of institutional approval and December 31, 2028.
2. Patients aged 18 years or older.
3. Patients who have provided informed consent to participate in the study.

Key exclusion criteria

Patients referred to a participating institution specializing in NTM-PD care who attended only one outpatient visit at that institution.

Target sample size

2000


Research contact person

Name of lead principal investigator

1st name Takahiro
Middle name
Last name Takazono

Organization

Nagasaki University Hospital

Division name

Department of Respiratory Medicine

Zip code

852-8501

Address

1-7-1 Sakamoto, Nagasaki

TEL

095-819-7273

Email

takahiro-takazono@nagasaki-u.ac.jp


Public contact

Name of contact person

1st name Kazuaki
Middle name
Last name Takeda

Organization

Nagasaki University Hospital

Division name

Department of Respiratory Medicine

Zip code

852-8501

Address

1-7-1 Sakamoto, Nagasaki

TEL

095-819-7273

Homepage URL


Email

k-takeda@nagasaki-u.ac.jp


Sponsor or person

Institute

Nagasaki University Hospital

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagasaki University Hospital Clinical Research Ethics Committee

Address

1-7-1, Sakamoto, Nagasaki

Tel

095-819-7726

Email

kenkyurinri@ml.nagasaki-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

札幌医科大学附属病院(北海道)、弘前大学病院附属病院(青森県)、新潟大学附属病院(新潟県)、富山大学附属病院(富山県)、慶応義塾大学病院(東京都)、独立行政法人国立病院機構東京病院(東京都)、公益財団法人結核予防会複十字病院(東京都)、国立国際医療センター病院(東京都)、独立行政法人国立病院機構東名古屋病院(愛知県)、独立行政法人国立病院機構近畿中央呼吸器センター(大阪府)、島根大学医学部附属病院(島根県)、福岡大学病院(福岡県)、産業医科大学病院(福岡県)、長崎大学病院(長崎県)、琉球大学病院(沖縄県)


Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2026 Year 08 Month 20 Day

Date of IRB

2026 Year 10 Month 15 Day

Anticipated trial start date

2026 Year 10 Month 15 Day

Last follow-up date

2028 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is a multicenter prospective observational study without study-mandated treatment interventions or treatment allocation. Data on diagnostic tests, treatment, and clinical course in routine clinical practice will be collected.
Patient characteristics, clinical practices at referring healthcare institutions, regional and institutional characteristics, diagnostic status, and reasons for referral will be evaluated. Associations between these factors and the time intervals to diagnosis, referral, and treatment initiation will be explored.
The primary outcome is the time (in days) from the first visit to the referring healthcare institution to the first visit to a participating institution specializing in NTM-PD care. This outcome will be assessed among referred patients for whom both dates are available.
Additional assessments will include the time intervals from symptom onset or detection of abnormal imaging findings to medical consultations, diagnostic testing, diagnosis, and treatment initiation, as well as treatment regimens, mycobacterial species distribution, antimicrobial susceptibility patterns, and clinical outcomes.


Management information

Registered date

2026 Year 11 Month 19 Day

Last modified on

2026 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072870